---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-265260"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2022-10-19T23:59:59+00:00"
generated_at: "2026-06-23T02:42:08.561949+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# President of R&D Judith Dunn resigns; position eliminated; CEO assumes direct oversight

## Summary
- Dr. Judith Dunn resigns as president, R&D; separation agreement signed October 14, 2022.
- Dunn remains employed through Jan 3, 2023, then provides biotech consulting in transitional capacity.
- Clinical development organization now reports directly to CEO Bryan Stuart; president R&D role eliminated.
- Company continues search for Chief Medical Officer as previously announced.
- Extended 6-month exercise period for stock options post-separation.

## SEC filing metadata
- accession: 0001193125-22-265260
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2022-10-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000119312522265260/0001193125-22-265260-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000119312522265260/d327131d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-265260
- JSON: https://secwatch.observer/filing/0001193125-22-265260.json
- Plain text: https://secwatch.observer/filing/0001193125-22-265260.txt

## Key facts
- Executive change
  Judith A. Dunn resigned as president, research and development at Fulcrum Therapeutics, Inc..
  - Action: resigned
  - Role: president, research and development
  source text: Dr. Judith A. Dunn entered into a separation agreement subsequent to Dr. Dunn’s resignation from her position as president, research and development.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000119312522265260/0001193125-22-265260-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.